Aller au contenu principal
Fermer

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
information fournie par Boursorama 02/10/2018 à 07:30

Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference


Strasbourg, France – October 2, 2018, 7:30 am CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, will be presenting three posters highlighting the Company’s world-leading viral vector expertise and their potential to transform the fight against cancer at the annual meeting of the Society for Immunotherapy of Cancer (SITC) to be held November 7-11 in Washington DC (USA).

They will cover:
- Invir.IO (TM): a new generation of multifunctional oncolytic viruses;
- myvac (TM): an individualized immunotherapy based on a viral vector (MVA);
- a next generation viral vector for cancer immunotherapy (PCPV).
.../...

Valeurs associées

0,6930 EUR Euronext Paris -0,43%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.

106,15 +0,03%
7 827,63 -0,07%
0,77 -3,27%
Or
4 156,07 -0,05%
1,12007 +0,03%
Chargement...